RSV Vaccine Study
Participants needed: Infants: 12-23 months
Do you want to protect your child against RSV?
About Respiratory Syncytial Virus (RSV)
- Respiratory syncytial virus (RSV) causes infection in all children by age 3. Itis still one of the childhood diseases for which we have no vaccine.
- RSV disease can cause mild illness (“cold”) in healthy children or spread to the lungs and cause severe illness. It is the leading cause of hospitalizations in infants under six months of age for breathing problems.
What is the purpose of this study?
- Researchers are developing a new RSV vaccine to protect infants from RSV disease, including bronchiolitis and pneumonia.
- This RSV vaccine has been given to adults, and findings of those tests showed that the side-effects were generally mild and predictable.
- This is the first study of this RSV vaccine to evaluate safety and immune responses against RSV.
Is my child eligible to participate?
- We are in need of infants between the ages of 12-23 months.
- The study involves a total of 12 visits to the IWK Health Centre over a two-year period.
- Visits will include blood tests, two injections of the study vaccinations or placebo, nose swabs to assess for RSV, physical exams, and questions about the child’s health by the study nurses and doctors.
You will receive:
- There will be no costs to you to take part in this study. As reimbursement for out-of-pocket expenses such as travel costs to and from study visits, you will receive $50 per visit for each visit and a parking pass at the end of each visit if required (if you park in the IWK parking garage).
- You will receive $600 in total ($250 paid out after study visit #4, $200 paid out after study visit #8 and $50 after the Day 60, 365 and final study visit).
- You will be compensated $50/visit for the monthly swab visits and any unscheduled visits.
Contact Cathy Brown
Phone (902) 470-7015